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A growing body of Australian and international literature has reported the benefits and 
improved health outcomes resulting from various trials of pharmaceutical care, self-
management support and other cognitive services in chronic conditions such as diabetes 
and obesity. This review will focus on existing medications, the reasons why they might not 
work for some individuals and the potential for new ways to treat both diseases. It will also 
review novel ways to manage the diseases, including using community pharmacy as a site 
for intervention, once effective therapies are available. 
The burden of diabetes and obesity for individuals and for the community is high. The 
complications of both diseases are related and of the order that adequate treatment and 
control are vital to limit an epidemic of severe morbidity and mortality. Medications 
and how they are used play a key role in the management of these chronic conditions. 
Current  antidiabetic therapies enhance insulin secretion by pancreatic beta-cells, reducing 
insulin resistance, modulating glucose metabolism or in type 1 diabetes or refractory 
type 2 diabetes, replacing insulin. Although several subclasses of non-insulin agents have 
been in use for some time, detailed information on their modes of action, use in various 
combinations and factors that prevent their optimal use are only recently emerging and 
require further understanding. Pharmacotherapy is also being increasingly used as a 
component of preventive programs targeting insulin resistance and obesity before onset 
of diabetes (‘prediabetes’), especially in children and adolescents. Pharmacists contribute 
significantly to quality use of medicines when they provide information, advice and 
recommendations to patients and providers to optimise therapeutic outcomes. In recent 
years, pharmacists have also sought to develop an expanded role in contributing to the 
management of chronic diseases to meet the needs of this growing patient population.
1  Woolcock Institute of Medical Research, Sydney Medical School, University of Sydney.
2  Faculty of Pharmacy, University of Sydney.
3  Discipline of Paediatrics, University of Sydney.
4 Institute of Endocrinology and Diabetes, Children’s Hospital, Westmead.
316 • A modern epidemic
Diabetes
Type 2 diabetes mellitus (T2DM), the most common form of diabetes, is now an escalating 
worldwide epidemic. It contributes significantly to premature mortality, morbidity 
and disability through the development of micro- and macrovascular complications of 
uncontrolled disease. In Australia, the 2007–2008 National Health Survey estimated that 
818  200 Australians (4%) have diabetes, based on self-reports [1]. The earlier national 
Australian Diabetes, Obesity and Lifestyle study found that approximately 1.2 million (7.4%) 
of Australians aged 25 years and over had diabetes with half of the respondents unaware 
[1]. A further 16% of Australians have been estimated to have impaired glucose metabolism 
or prediabetes [2]. The total economic burden is estimated at A$6 billion annually (2003) 
arising mainly from the costs associated with the treatment of complications [3].
The incidence and prevalence of T2DM in adolescents is increasing globally, but especially in 
those of non-white European descent [4]. The International Diabetes Federation estimates 
that 285 million people around the world have diabetes. This total is expected to rise to 
438 million within 20 years. Highest risk groups are those of black African descent, native 
North American, Hispanic, Asian, South Asian and Native Pacific Islanders. These groups 
have higher genetic risk factors with the clinical expression of T2DM being accelerated by 
increasing rates of childhood and adolescent overweight and obesity [5]. While T2DM is 
being seen in increasing prevalence in younger age groups, it is rarely seen until the second 
decade of life since it requires the trigger of the physiological increase in insulin resistance 
that occurs with puberty [4].
Obesity
Obesity is a major global public health and economic problem as it is associated with 
significant morbidity and mortality. In 2005, the World Health Organisation reported 
approximately 1.6 billion adults as overweight; 400 million of those were obese [6]. Australia 
is one of the most overweight developed nations [7], with a growing incidence over the last 
12 years, approximately 68% of adult men and 55% of adult women were overweight or 
obese in 2007–2008 [8]. The total cost of obesity in 2008 was A$58.2 billion which included 
the costs attributable to associated diseases [9].
Overweight and obesity are both disease states and risk factors for many other chronic 
conditions. Overweight is defined as a body mass index (BMI) ≥25 in adults or 85th 
percentile in children and adolescents and obesity as a body mass index ≥30 in adults or 
the 95th percentile in children and adolescents. Higher body mass was responsible for 7.5% 
of the total burden of disease and injury in 2003, ranked behind tobacco (7.8%) and high 
blood pressure (7.6%) [10].
Excess body mass predicts higher mortality and/or morbidity in cardiovascular disease, 
T2DM, some cancers and increasingly, osteoarthritis [11]. Obesity is also strongly 
associated with back, reproductive and mental health problems, and obstructive sleep 
apnoea. Modest weight losses of 5% to 10% have been shown to improve hypertension and 
dyslipidaemia [10, 12].
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In response to this problem the Australian Government recommended in June 2009, 
strategies for the treatment, management and prevention of obesity in ‘Weighing it up – 
obesity in Australia’, as well as better regulation of weight-loss products and programs to 
ensure safety and efficacy[9].
Addressing the problems
Evidence-based strategies addressing the problem of T2DM support the benefits of early 
interventions in prediabetes and strict control of glycaemia, blood pressure and lipids 
in established diabetes to reduce the risk and delay the onset of the complications such 
a cardiovascular and kidney disease [13–15]. In recent years, a plethora of clinical and 
management guidelines which recommend therapeutic targets to optimise disease control 
have become widely available to healthcare practitioners. This, coupled with advances in 
understanding of the pathophysiology of T2DM and the introduction of a range of new 
management therapies in the past decade, have ushered in the possibility of reducing the 
disease burden associated with T2DM and its complications. 
There is broad agreement that the most appropriate first-line therapy for overweight and 
obesity in all age groups is behavioural and lifestyle interventions, including nutritional 
and exercise interventions [16]. This is particularly so in children and adolescents in whom 
the problem is generally less entrenched and has fewer complications. Also, there is lower 
availability of licensed drugs for the use of obesity in children and adolescents and greater 
reluctance to use pharmacotherapy in the young because of concern about long-term side 
effects. The lessons of history have shown these concerns to be justified.
Management of T2DM 
The clinical management of T2DM aims to achieve control of glycaemia, as well as other 
risk factors such as blood pressure, dyslipidaemia and obesity to prevent or reduce the 
progression of the micro- and macrovascular complications associated with the condition. 
Initial and then ongoing management involves recommended modifications to diet and 
physical activity to address blood glucose as well as cholesterol and blood pressure. For 
blood glucose, if satisfactory glycaemic control is not achieved through weight loss and 
increased physical activity alone, pharmacotherapy is indicated. The current guidelines 
recommend that pharmacological therapy is commenced with metformin [17]. However, 
over time beta-cell function progressively declines, usually necessitating the addition of 
additional agents which include sulfonylureas, meglitinides, thiazolidinediones, and 
potentially incretin mimetics such as the oral DPPIV inhibitors, injectable agents such as 
exenatide, or insulin. The therapeutic use of each of these classes is discussed in the next 
section.
T2DM is a complex condition to manage, requiring all elements of the biopsychosocial 
model to be considered. Addressing lifestyle issues such as diet and exercise, as well as care 
in commencing and up-titrating medications, and vigilance in monitoring of the disease 
including achieving and sustaining blood glucose and other targets in therapy, is demanding 
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on the person with diabetes, their families and on healthcare resources. The membership of 
the health professional team that supports the person with T2DM is broad, and depending 
upon individual patient’s needs may include the general practitioner, practice nurse and 
dietitian, as well as the diabetes nurse educator, specialist endocrinologist, podiatrist, 
optometrist, ophthalmologist and psychologist. As described in later parts of this chapter 
the pharmacist can, and should, be an integral member of the healthcare team supporting 
the care of the person with diabetes.
The rest of this chapter will focus on pharmacotherapy for blood glucose in T2DM and 
pharmacotherapy in obesity, and management of these diseases in adults and adolescents. 
Commercial programs available for obesity management will be discussed, as well as 
optimising management of T2DM and obesity in our current health system and the 
evidence and potential role of pharmacy in improving outcomes for these diseases.
Optimisation of current therapies for diabetes
Current antidiabetic agents enhance the secretion of insulin by pancreatic beta-cells, 
improve insulin resistance in tissues or modulate glucose metabolism. Although several 
classes of drugs have been used in the treatment of diabetes for some time it is only recently 
that detailed information on their modes of action and the factors that prevent their optimal 
use in patients have emerged. 
Major classes of antidiabetic agents
(a) Insulin secretagogues
ATP is generated during mitochondrial glucose metabolism and modulates the opening of 
ATP-sensitive potassium channels on the plasma membrane. These channels are composed 
of eight polypeptides: four sulfonylurea receptor (SUR1) subunits that are members of the 
ATP-binding cassette transporter family and four Kir6 subunits that are members of the 
inwardly rectifying potassium channel family [18]. Hypoglycaemic sulfonylureas, such 
as glibenclamide, glipizide and tolbutamide, stimulate insulin secretion by interaction 
with SUR1. SUR1-induced closure of the ATP-sensitive potassium channel mediated by 
sulfonylureas depolarises the plasma membrane and promotes the release of insulin [19]. 
The meglitinides, such as repaglinide and nateglinide, are non-sulfonylurea insulin 
secretagogues whose mechanism of action resembles that of the sulfonylureas but is 
mediated through a different binding site on SUR1 [20]. Unlike the sulfonylureas, the 
meglitinides stimulate first-phase insulin release in a glucose-sensitive manner [21]. These 
properties enhance the control of serum glucose and insulin concentrations. 
(b) Insulin sensitisers
The storage of lipid in adipocytes and other cells is dysregulated in T2DM and desensitises 
insulin signalling. As a result, adipocytes do not store triglycerides adequately or release 
adipokines that regulate food intake. Thiazolidinediones are agonists for the nuclear 
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peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which regulates 
lipid storage in adipocytes [22]. These agents enhance insulin sensitivity by modulating 
the production of adipokines, including leptin, adiponectin, resistin and tumour necrosis 
factor-alpha, by adipocytes. By activating PPAR-gamma thiazolidinediones alter the 
transcription of genes that regulate glucose and lipid metabolism, such as lipoprotein 
lipase, fatty acyl-CoA synthase, glucokinase and the glucose transporter GLUT4. 
Although PPAR-gamma appears to be an important target for thiazolidinediones the 
receptor is expressed primarily in adipocytes. That these drugs improve insulin resistance 
in other cells that do not express PPAR-gamma suggests that there may be additional 
targets. Thus, thiazolidinediones may also target the adenosine monophosphate-activated 
protein kinase (AMPK), which is an important fuel sensor that regulates glucose and lipid 
metabolism. 
(c) Biguanides
The most important biguanide in current use is metformin but its mechanism of action 
is not entirely clear. In diabetic patients metformin decreases hepatic glucose output by 
decreasing gluconeogenesis and by increasing glucose uptake by skeletal muscle. However, 
it has also been shown that metformin activates AMPK in liver and muscle [23]. AMPK 
inhibits acetyl-coenzyme A carboxylase, which is the rate-limiting step of lipogenesis 
and down-regulates hepatic sterol-regulatory-element-binding-protein-1, which is a 
major regulator of lipogenic genes. This decreases triglyceride synthesis and facilitates the 
normalisation of lipid and glucose metabolism. 
(d) Incretin mimetics
Exenatide is the only drug in this group currently available in Australia. Exenatide binds 
to the human GLP-1 receptor, which provides glycaemic control via various mechanisms 
[24]. It is an insulin secretagogue that stimulates glucose dependent insulin secretion 
and therefore only works during hyperglycaemia but not during hypoglycaemia. The 
functioning of pancreatic beta-cells in patients with T2DM may also be improved by 
exenatide [24]. The secretion of glucagon is suppressed by exenatide, which lowers the 
blood glucose levels in both fasting and postprandial periods. 
Furthermore, exenatide delays gastric emptying in patients with T2DM [24]. This is 
very important in the regulation of postprandial blood glucose control, since the latter is 
strongly determined by the delivery of nutrients from the stomach to the small intestine. 
Exenatide also suppresses appetite, leading to a reduction in food intake and a decrease in 
body weight in the longer term usually of some kilograms.
It is indicated in Australia as adjunctive therapy to improve glycaemic control in patients 
with T2DM who are taking metformin, a sulfonylurea, or a combination of metformin and 
a sulfonylurea but are not achieving adequate glycaemic control.
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(e) DPP-IV inhibitors
Another new class of oral antidiabetic agents are the dipeptidyl peptidase IV inhibitors 
(DPP-IV) or ‘incretin enhancers’. They work by delaying the degradation of GLP-1 and 
thus extend the action of insulin in a glucose dependent manner, while also suppressing the 
release of glucagon [24]. There are currently three agents in this class approved in Australia: 
saxagliptin, sitagliptin and vildagliptin. 
(f) Alpha-glucosidase inhibitors
These agents, acarbose and miglitol, are taken orally and slow absorption of glucose by 
inhibiting alpha-glucosidases in the upper GI tract. These enzymes are responsible 
for converting complex polysaccharide carbohydrates into monosaccharides in a dose 
dependent fashion. They are less potent than other oral agents with an HbA1c lowering 
effect of 0.4% to 0.9% generally reported and are usually used in combination with other 
agents rather than as monotherapy [25]. 
(g) Insulin
Historically, insulin has been used late in the therapeutic cascade in T2DM after trial and 
failure to achieve targets through lifestyle modification and oral medications. Since decline 
in beta-cell function and reduced effectiveness of other agents over time is common in the 
pathophysiology of T2DM, many if not most patients will require insulin therapy, usually 
within ten years of the diagnosis of T2DM. In general, physicians have been reluctant to add 
insulin to therapy because of concerns about increased complexity, risk of hypoglycaemia 
and patient acceptance, and the possible need to commence insulin injections has been 
used as a motivator or ‘threat’ to improve lifestyle factors [26]. Yet insulin is the most 
efficacious agent to lower blood glucose levels in diabetes mellitus. A variety of insulin 
regimens are employed including simple basal supplements (with isophane, insulin-
glargine or insulin-detemir) to suppress hepatic glucose production, with the addition of 
prandial doses (regular human insulin or rapid-acting analogue) if needed to control meal-
related hyperglycaemia. Premixed insulin combinations are also frequently used. To date, 
insulin pump therapy has not been generally recommended as a means of insulin delivery 
in T2DM because simpler injection regimens are effective and cheaper; however increasing 
use is likely in subgroups with T2DM who have blood glucose levels that are difficult to 
stabilise. 
(h) Combination therapy
The agents outlined above are frequently used in combination, especially if glycaemic 
targets are not being met with single agents. As yet, there is no clear evidence as to which 
combinations are most effective or the order in which they are used and often the decision 
relates to individual patient factors and physician preference. The American Diabetes 
Association and the European Association for the Study of Diabetes have published a 
consensus algorithm for the metabolic management of T2DM [27]. The NHMRC of 
Australia has also published an algorithm as part of the Evidence-based clinical care 
Current therapies and pharmacy programs for obesity and diabetes • 321
guidelines in blood glucose control in type 2 diabetes [28]. In each of these guidelines, 
metformin is a cornerstone of therapy, often with the addition of a secretagogue agent as 
a second line and then the addition or substitution of insulin. A number of combination 
medications are available that combine metformin with a sulphonylurea, or with a DPP-IV 
inhibitor. We can expect changes in these drug therapy paradigms as experience is gained 
with newer agents such as incretin mimetics and the safety concerns with other agents (eg 
thiazolidinediones) are clarified. 
Adverse effects of current therapies and pharmacokinetic considerations
(a) Insulin secretagogues
The major side effect of sulfonylureas and meglitinides is hypoglycaemia, but this is usually 
mild and by definition is self-treated. Additional adverse effects of meglitinides include 
upper respiratory tract infections, rhinitis, bronchitis, dizziness and headache.
Pharmacokinetic studies have shown that serum concentrations of sulfonylureas and 
meglitinides are subject to marked inter-individual variation. Hepatic cytochromes P450 
(CYPs) 2C8, 2C9 and 2C19 mediate the phase I oxidation of most of these drugs. These 
CYPs exhibit polymorphisms that give rise to altered drug pharmacokinetics. The two major 
variant alleles of CYP2C9 – CYP2C9*2 and CYP2C9*3 – occur at frequencies of ~11% 
and ~7%, respectively, in Caucasians, but exhibit lower incidence in African-Americans 
and Asians [29]. These CYP2C9 polymorphisms influence the apparent clearance of 
tolbutamide, glimepiride and glibenclamide and may complicate therapy in Caucasians 
in particular [29]. In contrast, in vivo pharmacokinetics of gliclazide were dependent on 
CYP2C19. The poor metaboliser phenotype for CYP2C19 is important in Asians due to 
the higher incidence of defective CYP2C19*2 and *3 alleles (~20% in Asians, but only 2% 
in Caucasians). 
Repaglinide is eliminated by CYP2C8 and, to a lesser extent, CYP3A4-mediated 
oxidation to inactive phase I metabolites and by UDP-glucuronosyltransferases to the acyl 
glucuronide [30]. The CYP2C8*1/*3 genotype has been associated with decreased plasma 
concentrations of repaglinide. In comparison, nateglinide is metabolised by CYP2C9 and 
CYP3A4. However, the concordance between CYP2C alleles and the pharmacodynamics 
of these drugs is imperfect [29], and CYP2C genotyping to direct drug and dose selection 
is not currently indicated.
(b) Insulin sensitisers
Adverse effects of thiazolidinediones such as rosiglitazone and pioglitazone include weight 
gain and increase in peripheral fat mass, oedema, anaemia, pulmonary oedema, congestive 
heart failure and myocardial ischaemia [31]. Oedema is a drug class effect that precludes 
the use of the thiazolidinediones in patients with evidence of cardiac failure. The incidence 
of peripheral oedema was about 27% in one Australian study, which was reportedly 
somewhat higher than in other studies [31]. This was attributed to broader inclusion 
criteria or to the concurrent use of drugs such as non-steroidal anti-inflammatory drugs 
and calcium-channel blockers. 
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CYP2C8 is primarily responsible for the hydroxylation and N-demethylation of 
rosiglitazone in the human liver, with minor contributions from CYP2C9 [32]. By 
comparison, pioglitazone is oxidised by CYP2C8 and to a lesser extent by CYP3A4 [33]. 
The involvement of CYP3A4 in these pathways increases the potential for drug–drug 
interactions because this enzyme is involved in the metabolism of most drugs. CYP3A4 is 
also inducible by coadministered drugs including anti-epileptic agents and St John’s wort. 
Thus, avoidance of potent CYP3A4 inducers in patients receiving thiazolidinediones is 
advisable.
The future role of thiazolidinediones is increasingly uncertain because of safety issues, 
which also include an increased risk of fracture and osteoporosis as well as exacerbation 
of diabetic macular oedema in some patients [28]. Predominantly because of concerns 
about myocardial ischaemia risk, the use of rosiglitazone has been suspended in the 
European Union and restricted in the US [34] and additional warnings have been added 
in other countries, including Australia [35]. Recently pioglitazone has been reported to be 
associated with an increased risk of bladder cancer in those with the longest cumulative 
exposure; a safety warning has been issued by the FDA [36] and its use has been suspended 
in some countries. An earlier agent, troglitazone, was discontinued in 2000 because of 
concerns of liver toxicity [37].
(c) Biguanides
The most serious potential adverse effect of the biguanide class of oral hypoglycaemic 
agents is lactic acidosis. Phenformin was withdrawn some years ago because of high risk of 
lactic acidosis. However, metformin is safer than phenformin, and the risk of developing 
lactic acidosis is low, at less then one in 10 000 patients prescribed the agent [28], providing 
the drug is not used in patients from high-risk groups. Metformin itself causes few adverse 
effects with gastrointestinal upset the most common. 
Metformin does not undergo oxidative biotransformation and is excreted unchanged by 
the kidneys [38]. In normal renal function, metformin is unlikely to accumulate but is 
contraindicated in patients with risk factors for lactic acidosis or drug accumulation because 
of kidney, liver or cardiac dysfunction. Recently, it has been recognised in guidelines that 
metformin can be prescribed with vigilance, in people with stable chronic kidney disease 
down to an eGFR of 30 ml/min [28].
As per the product information, metformin may also lower serum vitamin B12 levels 
by reducing B12 absorption, and, while this vitamin is stored long term in the liver, it is 
prudent to assess the blood vitamin B12 level each couple of years to ensure it remains in 
the health range. 
(d) Incretin mimetics
Subcutaneously administered exenatide is generally well tolerated. The most frequently 
reported adverse effect is nausea which leads to a discontinuation of treatment in about 
2%–4% of patients although it usually improves with time [39]. The incidence of nausea is 
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higher during the initial weeks of treatment and declines thereafter. The observed weight 
loss in patients using exenatide is not associated with the occurrence of nausea. Other, 
usually minor and transient gastrointestinal complications such as vomiting and diarrhoea 
are also reported. Further adverse effects include feeling jittery, dizziness and headache 
[24, 39]. 
Severe hypoglycaemia causing unconsciousness, is rare in patients using exenatide. 
However, mild to moderate hypoglycaemia might occur more often with this agent, 
especially when used in combination with a sulphonylurea [24]. Similar to nausea, the 
incidence of hypoglycaemia peaks during the initiation of treatment and decreases over 
time. 
Because exenatide delays gastric emptying, it can influence the efficacy of agents that 
require rapid gastrointestinal absorption. Therefore, medications that depend on threshold 
concentrations such as oral contraceptives and antibiotics should be administered at least 
one hour before exenatide. 
Exenatide is administered by subcutaneous injection. The initial dosage should be 5 µg 
twice daily and if tolerated, should be increased to 10 µg twice daily after one month of 
treatment. Elimination of exenatide occurs mainly via glomerular filtration, hence the use 
of this agent is not recommended in patients with a severely impaired renal function. 
(e) DPP-IV inhibitors
These agents are generally well tolerated. The most common side effects are upper 
respiratory tract infection and headache. Use is also associated with abdominal pain, 
nausea and diarrhoea. A key advantage is that this class do not cause hypoglycaemia at 
nearly the rate of the sulphonylureas, nor do they cause weight gain [24]. 
(f) Alpha-glucosidase inhibitors
Flatulence and diarrhoea are the main, very common side effects of this class of drugs 
which often limit their use [25].
(g) Insulin
The predominant adverse effects with insulin therapy are risk of hypoglycaemia and weight 
gain. One target of therapy in people requiring insulin treatment is that hypoglycaemia 
should be minimised. Mild hypoglycaemia occurs in ~30% of people at least once a year. 
Severe hypoglycaemia, which may be life-threatening, through causing trauma or triggering 
heart events such as myocardial infarct, occurs in 1%–2% yearly [28]. Occurrence of 
severe hypoglycaemia should be a ‘red flag’ to the diabetes healthcare team that the entire 
treatment approach needs revision, to identify the precipitating and predisposing factors 
and prevent recurrence. 
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Variations in genes that influence the pharmacodynamics of antidiabetic drugs
(a) Insulin secretagogues
There is considerable inter-individual variation in the response to these drugs. Several 
SUR1 variants have been identified including common polymorphisms in exon 16 and 18. 
It has been suggested that the Ser1369Ala variant of the ABCC8 gene that encodes SUR1 
and also the Glu23Lys variant of Kir6.2 may be associated with the development of T2DM, 
especially if additional risk factors such as obesity are present [40].
(b) Insulin sensitisers
PPAR-gamma forms transcriptionally active heterodimers with RXR-beta so that defects in 
one or both genes may constitute an increased risk of insulin resistance. Thus, the common 
Pro12Ala variant of PPAR-gamma may contribute to the insulin resistant phenotype 
[41]. Obese individuals carrying the Ala-12 variant were at higher risk, especially if their 
dietary mono-unsaturated fatty acid intake was low. The observation that carriers of the 
RXR-beta C51T genotype who had a high body mass index also had an increased risk of 
gallstones may be relevant since both obesity and diabetes are important risk factors for 
gallstones [42]. Apart from possible contributions to disease development, as yet there is 
little information regarding the action of thiazolidinediones at variant PPAR-gamma.
(c) Biguanides
It now appears that AMPK is also a target for the biguanides. AMPK is a heterotrimeric 
complex containing a catalytic (alpha) subunit and two regulatory subunits (beta and 
gamma). In AMPK alpha2‐null mice body weight and fat mass were increased and 
insulin sensitivity was impaired when they were administered a high‐fat diet [43]. Single 
nucleotide polymorphisms in the AMPK alpha2 subunit gene were associated with altered 
serum lipoprotein concentrations in a patient cohort [44]. Similarly, relationships between 
diabetes and the –26C/T and IVS1+43C/T polymorphisms of the AMPK gamma2 subunit 
gene were evaluated. Patients who were homozygous for the –26T allele were associated 
with a higher risk of developing T2DM and patients who carried the IVS1+43TT variant 
had higher serum concentrations of triglycerides and cholesterol [45]. To date, information 
on the role of AMPK beta-subunit gene variation and disease development have not been 
delineated. Moreover, how AMPK subunit polymorphisms influence metformin efficacy in 
T2DM is yet to be established.
(d) and (e) Incretin mimetics and DPP-IV inhibitors
A single nucleotide polymorphism in the GLP-1 gene that encodes the major GLP-1 receptor 
variant, in which threonine 149 is replaced by methionine, is activated differentially by 
GLP-1 in vitro [46]. This receptor variant could account, in part, for different responses to 
GLP-1 agonists such as exenatide, but this possibility has not yet been actively explored.
With the exception of saxagliptin the available DPP-IV agents are not CYP substrates and 
so are seldom associated with pharmacokinetic drug-drug interactions. Vildagliptin has a 
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half-life of 2.8 hours and generates several metabolites by CYP-independent pathways [47], 
whereas the mean apparent half-life for plasma sitagliptin is 9–14 hours [48]. In contrast, 
saxagliptin is oxidised by CYPs 3A4 and 3A5 to a major metabolite that is pharmacologically 
active. Instead, renal excretion is the most important elimination pathway for the drugs. 
It has been established that dose adjustments are recommended for patients with renal 
impairment. 
Management of type 2 diabetes in adolescents
The principles of T2DM therapy in adolescents are similar to those in adults, although 
a much more limited range of pharmacological agents are approved and used. Again, 
lifestyle modification including nutritional components, physical activity and weight loss 
are first-line management tools [4]. However, in many instances, these are insufficient to 
meet treatment goals and the addition of pharmacotherapy is needed. In most countries, 
insulin and metformin are the only drugs approved for use in children and adolescents. 
Sulphonylurea agents are approved in fewer countries, but other agents have generally not 
yet had adequate appraisal of safety and efficacy in children and adolescents, and are not 
approved. The treatment options for T2DM in Adolescents and Youth (TODAY) study [49]
is a randomised trial evaluating three arms of pharmacological intervention for T2DM 
in newly diagnosed T2DM adolescents. It compares the efficacy of metformin alone or 
in combination with rosiglitazone or lifestyle intervention. However, as described earlier, 
there is increasing concern about emerging serious adverse effects of the thiazolidinediones 
in any age group and it is unlikely they will have a significant future role. In any case, their 
known class effect to cause weight gain [50] has always been a disincentive to their use in 
adolescents.
The choice of initial therapy in T2DM in adolescents depends on the clinical presentation 
including symptoms, severity of hyperglycaemia and presence or absence of diabetic 
ketoacidosis. The differentiation of type 1 from type 2 diabetes is not always clear at 
presentation in adolescents and T2DM can present with ketosis (up to 33%) or ketoacidosis 
(5%–25%) [51]. In those with severe hyperglycaemia and/or ketosis/ketoacidosis, initial 
treatment should always be with insulin for initial stabilisation and rapid metabolic control, 
in conjunction with lifestyle measures. Laboratory investigations (particularly type 1 
diabetes related antibodies and C-peptide) and clinical course will help clarify the diagnosis 
and it is common practice to add metformin and wean insulin to the point of cessation if 
possible. Asymptomatic patients will usually have a trial of lifestyle modification without 
drug therapy, while those with mild-to-moderate symptoms without ketosis will usually 
be treated with metformin in addition to lifestyle modification [52, 53]. The adequacy of 
ongoing therapy is judged by a number of clinical criteria, but mainly HbA1c <7% and 
fasting plasma glucose <7 mmol/l.
The proportion of adolescents with T2DM treated with lifestyle modification alone is 
reported to be 11%–50% [53]. However, as in adults, failure of therapy increases with 
duration. When lifestyle modification alone is inadequate, metformin is commonly added. 
Surveys indicate that a substantial proportion of adolescents with T2DM take metformin 
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(28%–71%) [53]. Metformin is approved by the FDA and also recommended by the 
American Diabetes Association and the International Society for Paediatric and Adolescent 
Diabetes as the first-line pharmacological agent in adolescents with T2DM. Doses up to a 
maximum of 2000 mg per day are usually recommended [53], divided twice daily, although 
the whole dose can be taken once a day using an extended release preparation which may 
improve gastrointestinal tolerability and compliance [54]. Metformin is also used as an 
adjunct to therapy in type 1 diabetes in adolescents with significant insulin resistance. A 
recent systematic review [55] (including adults and adolescents) demonstrated reduced 
insulin requirement with metformin, but no improved metabolic outcome and no data on 
cardiovascular outcomes are available.
When lifestyles measures and metformin are inadequate, or metformin is not tolerated 
or is contraindicated, insulin is added or substituted. Randomised controlled trials (RCT) 
comparing various insulin regimens in T2DM in adolescents do not exist, however data 
from adult experience are generally applicable. A bedtime long-acting insulin analogue 
is commonly used as initial insulin therapy, but a wide range of other regimens are used 
according to local preference, including multiple daily injections. Some guidelines in adults 
[56] suggest that isophane insulin should be used first and insulin analogues reserved for 
special indications. However there are some data to suggest lower rates of hypoglycaemia 
with analogues [57] and they are favoured as first-line insulin therapy by paediatric 
endocrinologists [53]. At present, insulin pump therapy is generally not recommended 
in T2DM [58, 59]. This is largely due to the increased intensity and cost of therapy, and 
because targets can often be met with simpler insulin therapy. However lower rates of 
hypoglycaemia and increased sensitivity to insulin when delivered by pump are attractive 
potential benefits.
Drugs other than metformin or insulin for adolescents with T2DM are not approved by 
regulatory authorities, although surveys indicate significant usage by some providers [53]. 
Newer agents such as GLP1 agonists and DPP4 inhibitors [50] may play a future role, 
especially in more difficult clinical situations. 
Management of obesity in adolescents
Lifestyle intervention through exercise and dietary modification should be the primary 
treatment for obesity in children and adolescents; drug therapy should be considered a 
secondary option in refractory situations and usually only in adolescents. Family-targeted 
behavioural and lifestyle intervention programs have been shown to have clinically 
significant benefits [16], although these benefits are not always sustained. Drug therapy 
used as an adjunct to lifestyle intervention in adolescents with obesity was analysed in 
a recent Cochrane review, including sibutramine, orlistat and metformin [16]. The use 
of sibutramine (a serotonin and noradrenaline reuptake inhibitor) in adolescents was 
examined in five studies, with data showing improved BMI over lifestyle alone; adverse 
events were greater in sibutramine than placebo-treated adolescents, but with low rates 
of any serious adverse events. Subsequently, however, sibutramine has been withdrawn 
from most parts of the world, including the US, Europe and Australia because of post-
Current therapies and pharmacy programs for obesity and diabetes • 327
marketing surveillance data which indicated increased risk of myocardial infarction and 
stroke in patients with existing cardiovascular disease [60]. In two available RCTs of orlistat 
(a gastrointestinal lipase inhibitor) in combination with lifestyle measures in adolescents 
there was also a greater improvement in BMI over placebo; however orlistat-treated 
patients had a much higher prevalence of gastrointestinal adverse effects, particularly oily 
stool evacuation, cramps, abdominal pain and increased defaecation, but also increased 
asymptomatic gallstones in one study [61]. While orlistat is still available, in May 2010 the 
FDA warned about a possible link with severe liver injury in rare cases [62], and labelling 
was revised to include this.
The most relevant drug used as an adjunct to lifestyle measures in adolescents with obesity is 
metformin, a biguanide oral hypoglycaemic agent. There are now several studies indicating 
its safety and efficacy in adolescents with insulin resistance and obesity (or prediabetes). 
In a recent systematic review and meta-analysis that included five suitable RCTs [63], 
metformin was concluded to have moderate efficacy in reducing BMI and insulin in 
hyperinsulinaemic obese children and adolescents, although no long-term studies were 
available. In pooled analysis, metformin reduced BMI by a mean 1.42 mg/m2 which was 
considered moderate compared to available data on subitramine (–1.66 kg/m2) or orlistat 
(–0.76 kg/m2) [16]. Gastrointestinal adverse events were more frequently reported in those 
receiving metformin (risk difference 10%–14%), but there were no serious adverse events. 
There is a need to further evaluate metformin in longer-term studies as an adjunct to more 
intensive lifestyle interventions [64]. Even without this further evidence, metformin is 
commonly used in clinical practice in adolescents with obesity, insulin resistance and other 
features of metabolic syndrome because of its favourable safety profile and its established 
use as pharmacotherapy in T2DM in adolescents.
Management of obesity in adults and commercial programs in Australia
There is a wide range of weight-loss programs available including commercial weight-
loss programs provided in the pharmacy as well as Jenny Craig and Weight Watchers, 
internet-based programs, weight-loss products such as meal replacements available 
from supermarkets, and community-based weight-management or exercise programs. 
The Weight Management Council of Australia provides a voluntary code of practice for 
commercial weight-loss companies [65]. Although commercial weight-loss programs 
are very popular, they usually only induce large short-term changes in weight and these 
changes are mostly transient. There is a need to establish evidence-based practices that 
demonstrate efficacy, safety and long-term weight maintenance. At this point in time there 
is very little data on the efficacy or outcomes of the commercial weight-loss programs in 
Australia [75].
Various factors affect an individual’s efforts in terms of short-term weight loss and 
maintenance [66]. The majority of overweight adults have a history of previous weight-
loss treatments. A study by Burke et al. (2008) examined individuals’ past experiences 
with weight-loss treatments [67]. Program features identified as least satisfying included 
dissatisfaction with diet product (20.4%) and concerns about safety of program or product 
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(17.2%). The most common reasons for difficulty in successfully losing weight that were 
identified were difficulty to make and maintain lifestyle change (38%), no time (32.4%) and 
lack of support (18.5%). Similarly, a study by Jeffery et al. (2004) examined how individuals’ 
attitudes about weight-loss efforts change during weight loss [68]. Individuals who lost 
less weight during the six months reported feeling more negative reactions. Reported 
satisfaction in relation to weight-loss effort declined over time, and in the last two months, 
perceived benefits were approximately equal to perceived costs of weight change.
Various studies have shown that superior weight loss occurs when cognitive behavioural 
therapy is added to diet and exercise interventions. Health education is required to facilitate 
patients making informed choices about their health. A study by Swift et al. (2009) showed 
that intended weight loss and outcomes were positively associated with health beliefs [69]. 
The results of this study also suggest that healthcare professionals may find it productive 
to discuss the social and aesthetic benefits associated with weight management. Cognitive 
strategies that have been identified in weight management include increasing awareness of 
negative thoughts, problemsolving alternatives to negative self-talk and pre-intervention 
strategies such as motivational interviewing and establishing objective weight-loss outcomes 
[70]. Establishing readiness for change via motivational interviewing has been shown to 
predict sustained change efforts in physical exercise, dietary change and adherence [70].
In all of these programs there is a need to clarify patients’ expectations for weight-loss 
outcomes, provide objective and realistic goals, and re-evaluate these goals over the course 
of management.
Management of type 2 diabetes and obesity in the health system 
There are a variety of effective therapies available and new approaches to be trialled in 
future. Notwithstanding the availability of effective therapies and treatment guidelines, 
translation of evidence into practice and delivering optimal care represents a significant 
challenge to healthcare systems. Because of the nature of T2DM and the need for patients 
to understand and take control of their lifestyle in order to reduce their health risk, people 
with T2DM are especially vulnerable and need intensive chronic disease management and 
ongoing support. From a systems perspective, however, limited patient access to diabetes 
healthcare professionals, as a result of personnel shortages [71], especially in rural and 
remote areas, and lack of systems to support chronic disease management with continuity 
of care [72, 73], are well recognised barriers to achieving optimal health outcomes for 
diabetes. Hence, there is a need to develop cost-effective innovative models of diabetes 
and weight management care based on more intensive continuity of care [74] including 
self-management support, regular monitoring and follow-up in order to enable patients to 
achieve the recommended targets.
Pharmacists in type 2 diabetes care
In recent years, pharmacists, as highly trained healthcare professionals with expertise in 
medicines, have sought to develop an expanded role in diabetes care to meet the burgeoning 
needs of this growing patient population. There are compelling arguments which support 
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this expanded involvement. Community pharmacies provide an established and visible 
network, extending to remote areas, of easily accessible healthcare professionals. Through 
regular and less formal contact than that with doctors, pharmacists are able to build strong 
relationships with patients and become a reliable source of information. Pharmacists 
can also have ongoing relationships with other healthcare providers and can serve as the 
‘bridge’ between healthcare providers and the patients, thus ensuring continuity of care. 
Therefore visits to the community pharmacy offer an excellent opportunity to screen at-risk 
patients and to provide education and support to diagnosed T2DM patients, particularly 
if they do not regularly visit a general practitioner (GP) or diabetes educator. In addition, 
as medications play a key role in preventing the complications of T2DM, ensuring their 
effectiveness through monitoring and adherence support as well as screening for drug 
-related problems, is critical to achieving improved health outcomes. 
Specific services that pharmacists have offered patients in T2DM include opportunistic 
screening for undiagnosed disease [76], diabetes self-management education, medication-
adherence support and medication management such as the at-home medicines review, 
ensuring the quality and evidence-based use of medications, monitoring clinical outcome 
measures eg blood glucose levels, blood pressure, lipid levels, and reminding patients of the 
importance of regular examinations for diabetic complications [77]. 
Two recent systematic reviews of the effects of these pharmacist–outpatient interventions 
on adults with diabetes mellitus showed significant improvements in HbA1C for patients 
in a diverse group of clinical settings and countries. Overall, the results suggest that 
pharmacist interventions can reduce long-term costs by improving glycaemic control and 
thus diminishing future diabetes complications [78, 79].
Diabetes care in Australian pharmacy
In 1999, a specialised T2DM service, the Diabetes Medication Assistance Service (DMAS), 
was developed for delivery in Australian community pharmacy. Its focus was on the 
provision of self-management support through a series of regular visits with a credentialed 
pharmacist to assist people with T2DM more effectively self-manage their condition and 
improve their use of medicines. At each visit, the pharmacist tailored the consultation to 
the individual needs of the patient. By using motivational interviewing and goal setting, in 
combination with education, the pharmacist aimed to empower the patient to take better 
control of their diabetes [80]. 
A systematic program of research involving two pilot studies, an RCT and an implementation 
trial has provided a strong evidence base for the clinical efficacy and cost-effectiveness 
of the DMAS. The RCT used a multi-site, control versus intervention, repeated measures 
design within five states in Australia. Fifty-six community pharmacies, 28 interventions 
and 28 controls, were randomly selected from a representative sample of urban and rural 
areas. Intervention pharmacies delivered the DMAS to patients with T2DM during the 
course of five visits to the pharmacy over a period of six months. Control pharmacists 
assessed patients at birth and six months and delivered no intervention. A total of 289 
patients (149 interventions and 140 controls) completed the study. Significantly greater 
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improvements in glycaemic control were seen in the intervention group compared to the 
control, ie a mean reduction in HbA1c of –0.97% (95% CI: –0.8, –1.14) in the intervention 
group compared with –0.27% (95% CI: –0.15, –0.39) in the control group. Improvements 
were also seen in blood pressure control and quality of life in the intervention group. 
Pharmacists identified a range of interventions (4309 for 149 patients) to improve the care 
and wellbeing of their patients. Monitoring of the progress of the disease and as well as 
the outcomes of the interventions appeared to be the essential element of the disease state 
management process. Both pharmacists and patients identified the outstanding benefits of 
the service and expressed great satisfaction with service provision. The DMAS was shown 
to be cost-effective when compared to other government funded programs [75].
The RCT was followed by a national implementation trial, the Diabetes Pilot Program 
(DPP) which aimed to answer three further questions regarding the DMAS service: 1) 
what are the key barriers and facilitators to national implementation of the DMAS service 
2) what is the optimal number of pharmacy visits and 3) what is the sustainability of 
clinical improvements beyond DMAS service delivery. A national quota sample of 90 
community pharmacies in Australia were randomly assigned into Group 1 (six-month 
DMAS) or Group 2 (12-month DMAS) and subsequently recruited a total of 524 patients. 
The implementation process was carefully tracked with data collected through individual 
or group interviews with 100 patients, 28 pharmacists and 41 GPs at the beginning and at 
the end of DMAS to explore their experiences and perceptions of DMAS and to identify 
barriers and facilitators. A wide range of clinical (HbA1c, blood pressure, lipids) and 
quality of life outcome measures were assessed.
The results indicated that the DMAS may be successfully implemented in diverse community 
pharmacy settings providing: 1) the pharmacy has adequate staff and infrastructure; 
2) there are good pharmacist-GP relationships; 3) the pharmacy has a pool of eligible 
patients; 4) there is effective promotion and integration of the DMAS within the healthcare 
sector; and 5) there is adequate remuneration for service delivery. The clinical outcomes 
of the implementation trial mirrored those of the RCT. Both the six-month and 12-month 
DMAS resulted in significant and similar reductions in HbA1c (–0.9; 95% CI:–0.65, –1.12), 
total cholesterol (–0.3; 95% CI:–0.07, –0.38), triglycerides (–0.3; 95% CI:–0.10, –0.53) and 
overall ten year CVD risk; moreover the benefits were sustained up to 12 months after the 
end of the DMAS [81]. The extent and sustainability of clinical improvements achieved by 
the DMAS together with the resulting reduction in cardiovascular risk should translate 
into future cost savings to healthcare systems by delaying and reducing diabetes related 
complications. Collectively these studies support the feasibility and efficacy of community 
pharmacy T2DM diabetes care in the Australian healthcare setting. 
In addition to the effectiveness of pharmacy support for people with T2DM, several studies 
have also supported the feasibility and efficacy of opportunistic screening for T2DM in 
community pharmacy [82–84]. Community pharmacy provides a logical site with its 
established, expansive and visible network of easily accessible health professionals, able to 
access a broad population who are apparently healthy and who rarely come into contact 
with GPs or nurses.
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Weight-management programs in community pharmacy
In the context of weight management in the UK, the government recognised the contribution 
that pharmacy can make in managing the obesity epidemic in the white paper Pharmacy 
in England [85]. In doing so, pharmacy contract negotiators recommended a government-
funded national weight-management service initiative in community pharmacies [86].
Several other studies have illustrated that community pharmacists’ involvement in weight-
loss programs has been associated with successful weight loss. A study in Denmark 
reported the results of ‘slimming courses’ held at 19 community pharmacies for 269 obese 
patients [87]. Average weight loss was 5.3 kg for females and 6.2 kg for males. At one year 
follow-up 20% of the patients who had completed the course had maintained a weight 
loss of greater than five kilograms [87]. Community pharmacists could play a key role in 
providing holistic weight-loss programs and collaborating with healthcare professionals, 
rather than being seen as product suppliers [88].
A recent Pharmacy Pulse survey showed that more than 17% of pharmacies in Australia 
want to be known as a destination for a weight-loss solution [89]. In 2003, the National 
Pharmacy Database Project reported that 8.7% of 1131 Australian community pharmacies 
surveyed conducted weight-management programs by trained staff [90]. At present, the 
majority of commercial weight-loss programs are based on very low-calorie diets that are 
mostly achieved by meal replacement shakes and soups. Other factors necessary for weight 
change such as increased physical activity are supplementary to the weight-loss product 
and used to augment the product specifically. Most programs provide ongoing support 
either by in-store consultants, a website or telephone support services. 
LifeweightTM was the first nationally released weight-management program specifically 
designed for community pharmacy. The program combines the product Xenical® (orlistat) 
with pharmacist-delivered cognitive services to provide a holistic package [75]. 
It was launched in 2004, following the decision to down schedule Xenical® (orlistat) from a 
prescription to pharmacist-only medication. The program was developed in collaboration 
with the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the 
Australian Institute of Pharmacy Management and Roche, the manufacturers of Xenical®. 
Training programs and resources were made available for pharmacists and pharmacy 
assistants to increase their skills in delivering the program. Content of the program is 
comprehensive and well structured, based on evidence-based material and is aligned with 
National Health and Medical Research Council guidelines [75]. Baseline and longitudinal 
patient data is collected including age, weight, body mass index, target weight, measured 
progress to target, final weight on completion of or withdrawal from the program. 
Adoption and uptake of LifeweightTM in community pharmacies has declined in recent 
times, as both consumers and pharmacists have articulated a need for a well-planned, 
accredited, community pharmacy-based, remunerated service that would deliver a more 
comprehensive collaborative service [91]. Such a service would ideally not be based on a 
product but a wholistic, evidence-based program. This would allow for increased numbers of 
overweight and obese Australians to have access to a consistent, evidence-based, integrated 
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healthcare weight-management program. Improvement in health for the overweight and 
obese, and better management of diabetes, hypertension, hypercholesterolemia and other 
obesity-related health issues would be the outcome. This would result in decreased costs to 
the healthcare system due to reduced mortality and morbidity attributed to the overweight 
and obese Australian population.
Conclusion
Innovation of service delivery is critical to address the burgeoning problems of T2DM, 
obesity and related diseases. The complications of these diseases place a considerable 
burden on the healthcare system.
The review of available pharmacotherapy for T2DM and obesity shows that there is 
considerable inter-individual variation in response to the various drug classes and the 
reasons for this are currently under investigation. In adolescents and children the approach 
to therapy is not merely a reflection of recommendations for adults. In terms of support 
for pharmacotherapy and lifestyle interventions, community pharmacy programs have 
provided evidence of effectiveness in T2DM, however at this point in time support for 
weight-loss programs has been inhibited by the focus on individual commercial products. 
Nevertheless, community pharmacists are a valuable resource of trained healthcare 
professionals that should be utilised to provide diabetes and obesity prevention and care 
services as part of an integrated primary care sector approach.
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